表紙
市場調査レポート

膀胱癌:パイプライン製品の分析

Bladder Cancer - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232863
出版日 ページ情報 英文 679 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
膀胱癌:パイプライン製品の分析 Bladder Cancer - Pipeline Review, H1 2016
出版日: 2016年04月30日 ページ情報: 英文 679 Pages
概要

当レポートでは、膀胱癌に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

膀胱癌の概要

治療薬の開発

膀胱癌:企業で開発中の治療薬

膀胱癌:大学/機関で研究中の治療薬

膀胱癌:パイプライン製品の概況

膀胱癌:企業で開発中の製品

膀胱癌:大学/機関で研究中の製品

膀胱癌の治療薬開発に従事している企業

膀胱癌:治療薬の評価

薬剤プロファイル

膀胱癌:最近のパイプライン動向

膀胱癌:休止中のプロジェクト

膀胱癌:開発が中止された製品

膀胱癌:製品開発のマイルストーン

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7982IDB

Summary

Global Markets Direct's, 'Bladder Cancer - Pipeline Review, H1 2016', provides an overview of the Bladder Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bladder Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Bladder Cancer
  • The report reviews pipeline therapeutics for Bladder Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Bladder Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Bladder Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Bladder Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Bladder Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Bladder Cancer Overview
  • Therapeutics Development
  • Bladder Cancer - Therapeutics under Development by Companies
  • Bladder Cancer - Therapeutics under Investigation by Universities/Institutes
  • Bladder Cancer - Pipeline Products Glance
  • Bladder Cancer - Products under Development by Companies
  • Bladder Cancer - Products under Investigation by Universities/Institutes
  • Bladder Cancer - Companies Involved in Therapeutics Development
  • Bladder Cancer - Therapeutics Assessment
  • Drug Profiles
  • Bladder Cancer - Recent Pipeline Updates
  • Bladder Cancer - Dormant Projects
  • Bladder Cancer - Discontinued Products
  • Bladder Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Bladder Cancer, H1 2016
  • Number of Products under Development for Bladder Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Bladder Cancer - Pipeline by 4SC AG, H1 2016
  • Bladder Cancer - Pipeline by ADC Therapeutics Sarl, H1 2016
  • Bladder Cancer - Pipeline by Advaxis, Inc., H1 2016
  • Bladder Cancer - Pipeline by Agenus, Inc., H1 2016
  • Bladder Cancer - Pipeline by Alligator Bioscience AB, H1 2016
  • Bladder Cancer - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016
  • Bladder Cancer - Pipeline by Altor BioScience Corporation, H1 2016
  • Bladder Cancer - Pipeline by AndroScience Corporation, H1 2016
  • Bladder Cancer - Pipeline by APIM Therapeutics AS, H1 2016
  • Bladder Cancer - Pipeline by Arno Therapeutics, Inc., H1 2016
  • Bladder Cancer - Pipeline by Astellas Pharma Inc., H1 2016
  • Bladder Cancer - Pipeline by AstraZeneca Plc, H1 2016
  • Bladder Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016
  • Bladder Cancer - Pipeline by Azaya Therapeutics, Inc., H1 2016
  • Bladder Cancer - Pipeline by Bavarian Nordic A/S, H1 2016
  • Bladder Cancer - Pipeline by Bayer AG, H1 2016
  • Bladder Cancer - Pipeline by BioCancell Ltd, H1 2016
  • Bladder Cancer - Pipeline by Biomics Biotechnologies Co., Ltd., H1 2016
  • Bladder Cancer - Pipeline by Bioncotech Therapeutics S.L., H1 2016
  • Bladder Cancer - Pipeline by Biotest AG, H1 2016
  • Bladder Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Bladder Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Bladder Cancer - Pipeline by Celgene Corporation, H1 2016
  • Bladder Cancer - Pipeline by Cellceutix Corporation, H1 2016
  • Bladder Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016
  • Bladder Cancer - Pipeline by Cold Genesys, Inc., H1 2016
  • Bladder Cancer - Pipeline by Corvus Pharmaceuticals, Inc., H1 2016
  • Bladder Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Bladder Cancer - Pipeline by DormaTarg, Inc., H1 2016
  • Bladder Cancer - Pipeline by Eisai Co., Ltd., H1 2016
  • Bladder Cancer - Pipeline by enGene, Inc, H1 2016
  • Bladder Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H1 2016
  • Bladder Cancer - Pipeline by Evotec AG, H1 2016
  • Bladder Cancer - Pipeline by Exelixis, Inc., H1 2016
  • Bladder Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Bladder Cancer - Pipeline by Five Prime Therapeutics, Inc., H1 2016
  • Bladder Cancer - Pipeline by Gene Signal International SA, H1 2016
  • Bladder Cancer - Pipeline by Genmab A/S, H1 2016
  • Bladder Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Bladder Cancer - Pipeline by Heat Biologics, Inc., H1 2016
  • Bladder Cancer - Pipeline by HEC Pharm Co., Ltd., H1 2016
  • Bladder Cancer - Pipeline by Hutchison MediPharma Limited, H1 2016
  • Bladder Cancer - Pipeline by Idera Pharmaceuticals, Inc., H1 2016
  • Bladder Cancer - Pipeline by ImmuNext, Inc., H1 2016
  • Bladder Cancer - Pipeline by Immunomedics, Inc., H1 2016
  • Bladder Cancer - Pipeline by Immupharma Plc, H1 2016
  • Bladder Cancer - Pipeline by LipoMedix Pharmaceutical Inc., H1 2016
  • Bladder Cancer - Pipeline by MacroGenics, Inc., H1 2016
  • Bladder Cancer - Pipeline by Meabco A/S, H1 2016
  • Bladder Cancer - Pipeline by Medicenna Therapeutics, Inc., H1 2016
  • Bladder Cancer - Pipeline by MedImmune, LLC, H1 2016
  • Bladder Cancer - Pipeline by Merck & Co., Inc., H1 2016
  • Bladder Cancer - Pipeline by Merck KGaA, H1 2016
  • Bladder Cancer - Pipeline by Mirati Therapeutics Inc., H1 2016
  • Bladder Cancer - Pipeline by NanoCarrier Co., Ltd., H1 2016
  • Bladder Cancer - Pipeline by NuCana BioMed Limited, H1 2016
  • Bladder Cancer - Pipeline by Omeros Corporation, H1 2016
  • Bladder Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H1 2016
  • Bladder Cancer - Pipeline by Oncolytics Biotech Inc., H1 2016
  • Bladder Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • Bladder Cancer - Pipeline by Optimum Therapeutics, LLC, H1 2016
  • Bladder Cancer - Pipeline by Pfizer Inc., H1 2016
  • Bladder Cancer - Pipeline by Pharma Mar, S.A., H1 2016
  • Bladder Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016
  • Bladder Cancer - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2016
  • Bladder Cancer - Pipeline by PsiOxus Therapeutics Limited, H1 2016
  • Bladder Cancer - Pipeline by Qu Biologics Inc., H1 2016
  • Bladder Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2016
  • Bladder Cancer - Pipeline by Rodos BioTarget GmbH, H1 2016
  • Bladder Cancer - Pipeline by Samyang Holdings Corporation, H1 2016
  • Bladder Cancer - Pipeline by Sanofi, H1 2016
  • Bladder Cancer - Pipeline by Savoy Pharmaceuticals, Inc., H1 2016
  • Bladder Cancer - Pipeline by Serometrix, LLC, H1 2016
  • Bladder Cancer - Pipeline by Shionogi & Co., Ltd., H1 2016
  • Bladder Cancer - Pipeline by Sorrento Therapeutics, Inc., H1 2016
  • Bladder Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016
  • Bladder Cancer - Pipeline by Stemline Therapeutics, Inc., H1 2016
  • Bladder Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016
  • Bladder Cancer - Pipeline by Synovo GmbH, H1 2016
  • Bladder Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2016
  • Bladder Cancer - Pipeline by Taiwan Liposome Company, Ltd., H1 2016
  • Bladder Cancer - Pipeline by Taris Biomedical LLC, H1 2016
  • Bladder Cancer - Pipeline by Telesta Therapeutics Inc., H1 2016
  • Bladder Cancer - Pipeline by Telormedix SA, H1 2016
  • Bladder Cancer - Pipeline by Theravectys SA, H1 2016
  • Bladder Cancer - Pipeline by Theryte Limited, H1 2016
  • Bladder Cancer - Pipeline by Tolero Pharmaceuticals, Inc., H1 2016
  • Bladder Cancer - Pipeline by Transgene SA, H1 2016
  • Bladder Cancer - Pipeline by UroGen Pharmaceuticals, Ltd., H1 2016
  • Bladder Cancer - Pipeline by Vakzine Projekt Management GmbH, H1 2016
  • Bladder Cancer - Pipeline by Vault Pharma Inc., H1 2016
  • Bladder Cancer - Pipeline by Vaxeal Holding SA, H1 2016
  • Bladder Cancer - Pipeline by Viralytics Ltd., H1 2016
  • Bladder Cancer - Pipeline by Viventia Bio Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Bladder Cancer Therapeutics - Recent Pipeline Updates, H1 2016
  • Bladder Cancer - Dormant Projects, H1 2016
  • Bladder Cancer - Dormant Projects (Contd..1), H1 2016
  • Bladder Cancer - Dormant Projects (Contd..2), H1 2016
  • Bladder Cancer - Dormant Projects (Contd..3), H1 2016
  • Bladder Cancer - Dormant Projects (Contd..4), H1 2016
  • Bladder Cancer - Dormant Projects (Contd..5), H1 2016
  • Bladder Cancer - Dormant Projects (Contd..6), H1 2016
  • Bladder Cancer - Dormant Projects (Contd..7), H1 2016
  • Bladder Cancer - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Bladder Cancer, H1 2016
  • Number of Products under Development for Bladder Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top